RCUS 241220 10.00P (RCUS241220P10000) Stock Options, News & Quotes

US OptionsDetailed Quotes

RCUS241220P10000

Watchlist

0.39
+0.19+95.00%

15min DelayClose Nov 27 16:00 ET

0.39High0.39Low

Intraday

5D
Daily

News

Barclays Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $29
Moomoo NewsNov 27 06:33 ET · Ratings
Arcus Biosciences Rises 10.5%
TipRanksNov 26 12:06 ET
BofA Securities Maintains Arcus Biosciences(RCUS.US) With Hold Rating, Maintains Target Price $22
Moomoo NewsNov 26 07:34 ET · Ratings
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Seeking AlphaNov 26 06:53 ET
Cautious Outlook on Arcus Biosciences Amid Uncertain TIGIT-Based Treatments
TipRanksNov 26 06:35 ET
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
BusinesswireNov 19 16:05 ET

Comments

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Meltyy

Apr 2 22:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Moomoo AI

Mar 22 05:31

The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.

Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding

Moomoo AI

Feb 23 04:42

Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.

Optimistic Investors Push Arcus Biosciences, Inc. (NYSE:RCUS) Shares Up 27% But Growth Is Lacking

Moomoo AI

Feb 13 04:49

Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation